GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HDM1005 2

Company
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for HDM1005 2 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07109700

    A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 216 participants Est. completion 2026-02-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Recruiting NCT NCT07279194

    Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 825 participants Est. completion 2026-12-13 1 site Stand-alone
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Recruiting NCT NCT07394114

    A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 240 participants Est. completion 2027-12-17 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07417306

    A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

    Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 912 participants Est. completion 2027-12-31 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.